Related Experiment Video
Updated: Dec 5, 2025
04:56
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
Published on: August 4, 2023
1.1K
Convalescent plasma appears efficacious and safe in COVID-19
Daulat Khulood1, Mir Shoebulla Adil2, Ruqiya Sultana3
1Dr. NTR University of Health Sciences, Vijayawada, India.
Therapeutic Advances in Infectious Disease
|October 16, 2020
Summary
Convalescent plasma (CP) therapy shows promise for treating coronavirus disease-19 (COVID-19), with most patients experiencing positive outcomes and few adverse events. Further randomized clinical trials are needed to confirm its safety and efficacy.
Area of Science:
- Infectious Diseases
- Immunotherapy
- Virology
Background:
- The emergence of SARS-CoV-2 caused a global pandemic with no established treatments.
- Convalescent plasma (CP) therapy has a history of use against viral infections like SARS, MERS, and H1N1.
- The World Health Organization identified CP as a potential treatment for MERS-CoV infections.
Purpose of the Study:
- To review the potential of convalescent plasma (CP) therapy for treating coronavirus disease-19 (COVID-19).
Main Methods:
- A review of eight studies involving 25,028 COVID-19 patients over 18 years old treated with CP therapy.
- Analysis of reported outcomes and adverse events associated with CP treatment.
Main Results:
- The majority of patients treated with CP therapy showed favorable outcomes.
- Serious adverse events were reported in less than 1% of patients receiving CP therapy.
Conclusions:
- CP therapy demonstrates promising benefits for severely ill COVID-19 patients.
- Further randomized clinical trials are essential to validate the safety, efficacy, and tolerability of CP therapy.
- Given the lack of effective pharmacological options, CP therapy is a reasonable consideration pending RCT confirmation.
